Navigation Links
IRS Awards Cash Grant to Advanced Life Sciences Under the Qualifying Therapeutic Discovery Project
Date:11/3/2010

CHICAGO, Nov. 3, 2010 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that the Company has been awarded a cash grant under the Qualifying Therapeutic Discovery Project which was created by Congress as part of the Patient Protection and Affordable Care Act of 2010. In July 2010, the Company applied for the grant to help fund the development of Restanza™, a novel once-daily oral antibiotic for the treatment of community acquired bacterial pneumonia (CABP).

(Logo:  http://photos.prnewswire.com/prnh/20080218/ALSLOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO)

The tax credit is targeted to projects that show a reasonable potential to: (i) develop new treatments that address "unmet medical needs" or chronic and acute diseases; (ii) reduce long-term health care costs; (iii) represent a significant advance in finding a cure for cancer; (iv) advance U.S. competitiveness in the fields of life, biological, and medical sciences; or (v) create or sustain well-paying jobs, either directly or indirectly. The total award granted to the Company was $244,479.25 which represents the maximum allocated amount per qualifying project.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company's lead candidate, Restanza™, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including CABP and biodefense pathogens including anthrax, plague and tularemia. For more information, please visit us on the web at www.advancedlifesciences.com or follow us on twitter at http://twitter.com/advancedlifesci.

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements represent our management's judgment regarding future events.  The Company does not undertake any obligations to update any forward-looking statements whether as a result of new information, future events or otherwise.  Our actual results could differ materially from those discussed herein due to several factors including the success and timing of our clinical trials and our ability to obtain and maintain regulatory approval and labeling of our product candidates; our plans to develop and commercialize our product candidates; the loss of key scientific or management personnel; the size and growth of potential markets for our product candidates and our ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of our estimates regarding expenses, future revenues and capital requirements; our ability to obtain financing on terms acceptable to us; our ability to obtain and maintain intellectual property protection for our product candidates; the successful development of our sales and marketing capabilities; the success of competing drugs that become available; and the performance of third party collaborators and manufacturers.  These and additional risks and uncertainties are detailed in the Company's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. 2010 Lasker Awards Honor Trailblazers in Medical Research and Clinical Care
2. Talecris Biotherapeutics GmbH Awards Winners of the 7th Annual European ALTA Research Fellowship at 2010 ERS Meeting
3. Octapharma Grants Program Awards First Research Grant to Rush University Medical Center
4. NeoStem Named Best Stem Cell Company in The New Economys 2010 Biotech Awards
5. Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards
6. 2010 Michael E. DeBakey Journalism Awards Announced
7. Medical Writer Rita Buckley Wins Awards for Excellence in Medical Communication
8. Knome Announces KnomeDISCOVERY Research Awards Program
9. Siemens/Talecris Win Best Partnership in the Outsourcing Excellence Awards
10. BIO-IT World Announces the Winners of its 2010 Best Practices Awards Program
11. Another Top 10 Pharmaceutical Company Awards Cardiac Safety Study to iCardiac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... According to world renowned prostate cancer surgeon, ... patients traditionally had two main treatment options: surgery or radiation. Based on a patient’s ... New technology has enabled doctors to administer higher doses of radiation to ...
(Date:5/2/2016)... ... , ... StarNet Communications Corp, ( http://www.starnet.com/ ) a leading publisher of remote ... modules to its flagship X-Win32 PC X server. The new modules enable X-Win32 ... PC over encrypted SSH. , Traditionally, users of PC X servers deploy the XDMCP ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... devices used in spinal surgical procedures, today announced the completion of a significant ... proposition for current and future customers and partners. Kohlberg & Company, L.L.C. ...
(Date:4/29/2016)... ... ... Implant Systems announced today that the two-level components for the Revolution™ Spinal System were ... components expand the capabilities of the system and allow Revolution™ to be utilized for ... company has seen significant sales growth in 1Q 2016, and the system is currently ...
Breaking Biology Technology:
(Date:3/3/2016)... , March 3, 2016  FlexTech, a SEMI ... categories of Innovation, Research & Development, Leadership in Education, ... This is the 9 th year of the ... of companies and individuals from past years . ... on a pre-described set of criteria, by a panel ...
(Date:3/3/2016)... and DE SOTO, Kansas , March ... Detection Plus® to offer Oncimmune,s Early CDT®-Lung, a ... early detection of lung cancer Early CDT®-Lung ... and individuals. --> Early CDT®-Lung test to ... --> Oncimmune, a leader in early cancer ...
(Date:3/2/2016)... 2016 http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) ... "Global Biometrics as a Service Market 2016-2020" ... --> http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has announced the ... a Service Market 2016-2020" report to ... and Markets ( http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has announced ...
Breaking Biology News(10 mins):